Dr. Roger Kenneth Hershline PhD MD, Global Humanceuticals, Inc and CureHIV apply to Bill and Melinda Gates' Grand Challenges in Global Health to fund the new HIV non-traditional drug LiSAVIOR. Current drug and vaccination treatments do not treat the growth of HIV in the gastrointestinal tract. - April 02, 2008
Dr. Roger Kenneth Hershline PhD MD, Chairman and Founder of CureHIV.us, agreed to provide samples of Global Humanceuticals, Inc’s NIAID#11039, a new powerful class of anti-HIV drug to clinical researchers. The drug is able de-activates the virus even if diluted nearly a billion times. - September 09, 2007
Dr. Hershline states that, baring a new preventative, CureHIV now predicts over 700 million worldwide HIV infected humans by the New Year 2018, as this global pandemic emerges. - July 15, 2007
|
